Epic Bio, a biotechnology company, has announced its launch, along with $55 million raised in series A financing.
Epic Bio specializes in modulating gene expression in vivo. It developed the Gene Expression Modulation System, the most extensive known collection of modulators that will be used to design guide RNAs specialized in targeted genes, according to a July 12 company news release.
Epic Bio founder Stanley Qi, PhD, is co-inventor on the CRISPR patent held by the University of California. Dr. Qi’s background in epigenetics and CRISPR led him to found Epic Bio.